• Sanaullah Jan Associate Professor, Vitreo-Retina division, Ophthalmology Department, Hayatabad Medical Complex, Peshawar.
  • Muhammad Nazim Hayatabad Medical Complex
  • Samina Karim Trainee Vitreoretina Hayatabad Medical Complex, Peshawar.
  • Zakir Hussain Trainee Vitreoretina, Hayatabad Medical Copmlex, Peshawar.


Background: Bevacizmab is still an unlicensed drug for intraocular use in spite of the fact that it has shown comparable efficacy to other anti-vascular endothelial growth factors (anti-VEGF) medications in some large sample randomized control trails. Although repackaged bevacizumab has got safety concerns but its use is growing because of easy availability and low cost. Our study focuses on the diverse and growing indications of intravitreal bevacizumab (IVB) and its ocular complications in our geographical setting. Method: This interventional case series was carried out at my private practice in Said Anwar Medical Complex, Dabgari, Peshawar, from January 2008 to July 2015. Total of 6107 injections were given to 4352 eyes. Intravitreal bevacizumab was injected in proper operating room setting. Bevacizumab injections were prepared from same vial by multiple withdrawals taking care of aseptic precautions. Follow up was done at 1 week and 20 days and adverse effects were noted. Results: Diabetic macular oedema (36%), central retinal vein occlusion (17.6%) and branched retinal vein occlusion (11%) were the top three indications of IVB. Other common indications were proliferative diabetic retinopathy (9.6%), neo-vascular glaucoma (5.9%), proliferative diabetic retinopathy with vitreous bleed (4.4%), proliferative diabetic retinopathy with tractional retinal detachment (3.7%), neo-vascular age related macular degeneration (2.9%), central serous retinopathy (1.48%) and Eale’s disease (1.48%). Endohthalmitis occurred in 3 eyes (0.069%) while retinal detachment was found in only 2 eyes (0.046%).Conclusion: Common indications of bevacizumab are diabetic macular oedema, central retinal vein occlusion and branched retinal vein occlusion. Complications like endophthalmitis and retinal detachment are rare.Keywords: Intravitreal bevacizumab, Avastin, Endophthalmitis

Author Biography

Muhammad Nazim, Hayatabad Medical Complex

Vitreoretina trainee HayatabadMedical Complex, Peshawar.


Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injections of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27(7):787–94.

Eadie JA,Gottlieb JL,Ip MS,Blodi BA,Danis RP,Chandra SR,et al. Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina2014;45(5):394–7.

Campochiaro PA, HeierJS, Feiner L,Gray S, Saroj N, Rundle AC,et al.Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study.Ophthalmology2010;117(10):1102–12.

Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, et al.Intravitrealaflibercept for macular edema following branch retinal vein occlusion: The 24-week results of the VIBRANT study.Ophthalmology2015;122(3):538–44.

Stein JD, Newman-Casey PA,Mrinalini T, Lee PP, Hutton DW. Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neo-vascular Macular Degeneration. Ophthalmology 2014;121(4):936–45.

Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, GrundwalJE, et al. Ranibizumab and Bevacizumabfor Treatment of Neo-vascular Age-related Macular Degeneration:Two-Year Results. Ophthalmlogy 2012;119(7):1388–98.

Wells JA,Glassman AR,Ayala AR,JampolLM,Aiello LP,Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.N Engl J Med 2015;372(13):1193–203.

ArevaoJF, Lasave AF, Wu L, Diaz-Lopis M, Gallego-Pinazo R, Alezzendrini AA,et al. IntravitrealBevacizumab plus grid laser photocoagulation or intravitrealbevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of Pan-American Collaborative Retina Study Group at 24 months. Retina 2013;33(2):403–13.

Pachuo MA, Sahto AA, Quraishi MH, Abbasi AM. Role of post injection antibiotics after intravitrealbevacizumab injection in preventing endophthalmitis. Pak J Ophthalmol2015;31(1):44–7.

Poku E, Rathbone J, Wong R, Everson-Hock E, Essat M, Pandor A,et al.The safety of intravitrealbevacizumabmonotherapy in adult ophthalmic conditions: systematic review. BMJ Open2014;4(7):e005244.

McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31(4):654–61.

Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26(7):1587–97.

Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. SurvOphthalmol 2012;57(4):347–70.

Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Status Date New Search Stud Content UpdatConclus Chang Publ In. 2015;1(8).

Bressler SB, Qin H, Melia M, Bbressler NM,Beck RW, Chan CK,et al. Exploratory analysis of the effect of intravitrealranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013;131(8):1033–40.

Ghayoor I, Bokhari SA, Kamil Z, Shakir M, Zafar S, Khan MA. To assess the effect of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion. Pak J Ophthalmol 2012;28(2):60-5.

Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitrealbevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond) 2013;27(12):1339–46.

Patwardhan SD, Azad R, Shah BM, Sharma Y. Role of intravitrealbevacizumab in Eale’s disease with dense vitreous hemorrhage: a prospective randomized control study. Retina 2011;31(5):866–70.

Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, et al. Intravitrealbevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology2009;116(8):1481–7.

Michael E, Emily YC, Lawrence AY. Macular Telangiectasia. In: Ryan SJ, editor. Retina. 5th ed. London: Saunders/Elsevier; 2013. p.1050–7.

Kevin G, Mark EP, Richard GW. Retinitis Pigmentosa And Allied Disorders. In: Ryan SJ, editor. Retina. 5th ed. London: Saunders/Elsevier; 2013. p.762–822.

Shoughy SS, Kozak I. Updates in uveitic macular edema. World J Ophthalmol 2014;4(3):56–62.

Goel N, KumarV, SethA. Role of intravitrealbevacizumab in adult onset Coat’s disease. IntOphthalmol 2011;31(3);183–90.

Finger RP, CharbelLesa P, Schmitz-Valckenberg S, Holz FG, Scholl HN. Long term effectiveness of intravitrealbevacizumab for choroidal neo-vascularization secondary to angiod streaks in pseudoxanthomaelasticum. Retina 2011;31(7):1368–78.

Parodi MB, LaconoP,Papayannis A, Sheth S, Bandello F. Laser photocoagulation, photodynamic therapy and intravitrealbevacizumab for the treatmentofjuxtafovelchoroidal neo-vascularization secondary to pathological myopia. Arch Ophthalmol 2010;128(4):437–42.

Fung AE, Rosenfield PJ, Reichel E. The international intravitrealbevacizumab safety survey using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90(11):1344–9